Overview: FSH Immunohistochemistry TestIntroduction: The FSH Immunohistochemistry Test detects follicle-stimulating hormone (FSH) to diagnose pituitary tumors, causing hormonal imbalances or fatigue. Aligned with 2023 Endocrine Society guidelines, it uses immunohistochemistry for high specificity, supporting endocrine screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected pituitary disorders.
Other Names: FSH IHC Assay, Pituitary Tumor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: FSH testing began in the 1980s with pituitary research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects FSH to diagnose pituitary tumors, guides treatment, and evaluates patients with hormonal imbalances or fatigue.
Test Parameters: 1. Follicle-Stimulating Hormone
Pretest Condition: No fasting required. Collect tissue via pituitary biopsy or surgery. Report history of hormonal imbalances, fatigue, or infertility.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document hormonal imbalances, fatigue, infertility, or family history of pituitary disorders. Include current medications, especially hormone therapies.
Consent: Written consent required, detailing the tests purpose, pituitary tumor implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect FSH in pituitary tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for pituitary tumor diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive FSH staining suggests pituitary tumors (e.g., FSH-secreting adenomas), guiding surgery or medical therapy. Negative staining may require further endocrine testing.
Specialist Consultation: Consult an endocrinologist or neurosurgeon for result interpretation and treatment planning.
Additional Supporting Tests: LH IHC, pituitary MRI, or FSH serum levels to confirm pituitary tumor diagnosis.
Test Limitations: Not specific to one pituitary tumor type; clinical correlation is needed. Other conditions may affect staining.
References: Endocrine Society Pituitary Guidelines, 2023; Journal of Clinical Endocrinology, Fleseriu M, 2022.
